The US FDA Center for Biologics Evaluation and Research prefers that convalescent plasma treatments for coronavirus be studied in traditional clinical trials. • Source: Shutterstock
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
